Development of artificial siderophores, antibacterial drugs and siderophore-drug conjugates against pathogenic bacteria
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 472 Seiten
- Sprache
-
Englisch
- Anmerkungen
-
Braunschweig, Technische Universität Braunschweig, Dissertation, 2022
- Schlagwort
-
Antibiotikum
Arzneimittelresistenz
Antimikrobieller Wirkstoff
Mikroorganismus
- Ereignis
-
Veröffentlichung
- (wo)
-
Braunschweig
- (wer)
-
Technische Universität Braunschweig
- (wann)
-
2023
- Urheber
-
Zscherp, Robert
- Beteiligte Personen und Organisationen
- URN
-
urn:nbn:de:gbv:084-2023011709164
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:50 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zscherp, Robert
- Klahn, Philipp
- Werz, Daniel B.
- Technische Universität Braunschweig
Entstanden
- 2023
Ähnliche Objekte (12)
Oligosaccharides based antibacterial drug conjugates
Chemoselective synthesis of functional drug conjugates
Antiparasitic and antibacterial drug discovery : from molecular targets to drug candidates
Development of peptide-drug conjugates targeting mitochondria
Peptide-drug conjugates for advanced targeted cancer therapy
Improved Drug Delivery of next-generation Antibody-Drug Conjugates by utilizing tumor-associated proteases
Transferrin‐coated nanodiamond–drug conjugates for milliwatt photothermal applications
Poly(glycerol adipate) - indomethacin conjugates for modified drug release
Antibody–drug conjugates as an emerging therapy in oncodermatology
Fc Antigen-Binding Fragment Drug Conjugates as Novel Antibody-Based Format for Targeted Drug Delivery
Overcoming drug resistance by stimulus-sensitive drug delivery systems : a preclinical characterization of polymer-drug conjugates for the treatment of multi-drug resistant cancer
Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies
Oligosaccharides based antibacterial drug conjugates
Chemoselective synthesis of functional drug conjugates
Antiparasitic and antibacterial drug discovery : from molecular targets to drug candidates
Development of peptide-drug conjugates targeting mitochondria
Peptide-drug conjugates for advanced targeted cancer therapy
Improved Drug Delivery of next-generation Antibody-Drug Conjugates by utilizing tumor-associated proteases
Transferrin‐coated nanodiamond–drug conjugates for milliwatt photothermal applications
Poly(glycerol adipate) - indomethacin conjugates for modified drug release
Antibody–drug conjugates as an emerging therapy in oncodermatology
Fc Antigen-Binding Fragment Drug Conjugates as Novel Antibody-Based Format for Targeted Drug Delivery
Overcoming drug resistance by stimulus-sensitive drug delivery systems : a preclinical characterization of polymer-drug conjugates for the treatment of multi-drug resistant cancer
Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies
Oligosaccharides based antibacterial drug conjugates
Chemoselective synthesis of functional drug conjugates
Antiparasitic and antibacterial drug discovery : from molecular targets to drug candidates
Development of peptide-drug conjugates targeting mitochondria
Peptide-drug conjugates for advanced targeted cancer therapy
Improved Drug Delivery of next-generation Antibody-Drug Conjugates by utilizing tumor-associated proteases
Transferrin‐coated nanodiamond–drug conjugates for milliwatt photothermal applications
Poly(glycerol adipate) - indomethacin conjugates for modified drug release
Antibody–drug conjugates as an emerging therapy in oncodermatology
Fc Antigen-Binding Fragment Drug Conjugates as Novel Antibody-Based Format for Targeted Drug Delivery
Overcoming drug resistance by stimulus-sensitive drug delivery systems : a preclinical characterization of polymer-drug conjugates for the treatment of multi-drug resistant cancer